Past issues · Cancer intelligence · Vivonco

OpenCareby Vivonco

Find a cancer doctor25,000+ oncologists across the US Cancer hospitalsNCI centers and accredited hospitals Know your cancerYour report and treatments, in plain words First week checklistThings to check or ask How to payInsurance, drug costs, grants Clinical trialsNew treatments, near you first SupportHelplines, rides, places to stay DietWhat to eat, by cancer and treatment

All help in one place

Advanced therapies

Second opinionsFrom the 25 best cancer hospitals Top cancer centersWho runs the most trials for your cancer Newer treatmentsCAR-T, radioligand, proton and more Not approved for you yetExpanded access, Right to Try

All advanced therapy options

Search/

/

Try

Talk to us Get your plan› Sign in

My recordCare team

Your saved plans

Open my record Care team Sign in

Menu

Get your plan› My record Sign in to your record Find help Find a cancer doctor25,000+ oncologists across the US Cancer hospitalsNCI centers and accredited hospitals Know your cancerYour report and treatments, in plain words First week checklistThings to check or ask How to payInsurance, drug costs, grants Clinical trialsNew treatments, near you first SupportHelplines, rides, places to stay DietWhat to eat, by cancer and treatment Advanced therapies Second opinionsFrom the 25 best cancer hospitals Top cancer centersWho runs the most trials for your cancer Newer treatmentsCAR-T, radioligand, proton and more Not approved for you yetExpanded access, Right to Try For doctors Talk to us Newsletter

Care team Sign in

Skip to content

Cancer intelligence Latest issue Weekly roundup Past issues

Past issues

32 issues so far, newest first.

November 2026 No. 28 · Wed, Nov 4 Shorter radiation matched standard control in high-risk breast cancer No. 27 · Tue, Nov 3 Durvalumab combination improved outcomes in muscle-invasive bladder cancer No. 26 · Mon, Nov 2 Removing GALE boosted immune cell killing in colorectal cancer models Nov 1 Weekly roundup. Personalized vaccine results diverged by cancer type: melanoma recurrence fell, while the pancreatic vaccine missed its main goal, so vaccine programs need evidence for each disease. October 2026 No. 25 · Sat, Oct 31 Selpercatinib improved outcomes in advanced medullary thyroid cancer No. 24 · Fri, Oct 30 Blood markers predicted outcomes in metastatic prostate cancer No. 23 · Thu, Oct 29 Divarasib improved survival in advanced non-small cell lung cancer No. 22 · Wed, Oct 28 Sacituzumab tirumotecan improved survival in triple-negative breast cancer No. 21 · Tue, Oct 27 Personalized vaccine cut recurrence risk in melanoma after surgery No. 20 · Mon, Oct 26 Nivolumab combination did not improve outcomes in bladder cancer Oct 25 Weekly roundup. Treatment choices are increasingly linked to tumor or blood markers, supporting a shared testing service that helps match patients to targeted regimens. No. 19 · Sat, Oct 24 Moderna vaccine almost halves melanoma recurrence risk No. 18 · Fri, Oct 23 Ablation did not improve survival in oligometastatic breast cancer No. 17 · Thu, Oct 22 Shorter radiation matched standard treatment after breast cancer mastectomy No. 16 · Wed, Oct 21 Chimeric antigen receptor therapy helped in diffuse large B-cell lymphoma No. 15 · Tue, Oct 20 Shorter radiation course matched standard treatment for high-risk breast cancer No. 14 · Mon, Oct 19 D2C7-ATC was tested in recurrent brain cancer Oct 18 Weekly roundup. Personalized vaccines are moving from immune responses in ovarian cancer trials toward broader testing No. 13 · Sat, Oct 17 Serplulimab combination delayed progression in pancreatic cancer No. 12 · Fri, Oct 16 Anselamimab missed its main target in amyloidosis trial No. 11 · Thu, Oct 15 Guideline recommends immunotherapy with chemotherapy for advanced biliary tract cancer No. 10 · Wed, Oct 14 Anito-cel led to responses in multiple myeloma trial No. 9 · Tue, Oct 13 Retlirafusp alfa combo extended survival in advanced stomach cancer No. 8 · Mon, Oct 12 Nivolumab led to responses in advanced solid cancers Oct 11 Weekly roundup. India’s 30% margin cap targets ₹2,500 Cr annual savings, making affordable regimens and help navigating medicine costs central to patient access. No. 7 · Sat, Oct 10 FDA approves atezolizumab with chemotherapy for stage III colon cancer No. 6 · Fri, Oct 9 FDA approves tucatinib combination for maintenance treatment of breast cancer No. 5 · Thu, Oct 8 Ablation did not improve outcomes in oligometastatic breast cancer No. 4 · Wed, Oct 7 FDA approves daraxonrasib for pancreatic cancer No. 3 · Tue, Oct 6 FDA approves daraxonrasib for pancreatic cancer No. 2 · Mon, Oct 5 A mutation linked to cisplatin resistance in hypopharyngeal squamous cell carcinoma No. 1 · Sat, Oct 3 Pembrolizumab and olaparib delayed growth in advanced ovarian cancer

Get it by email

Free. Monday to Saturday, with a weekly roundup on Sundays.

Start with your reports.

Get your plan Get other help

Cancer intelligence, every day and every week. The research, trials and approvals that matter, in one short email. Free.

OpenCareby Vivonco

Understand your cancer. Find the right doctor, the right hospital and the help to pay for it.

Find help

Find a cancer doctor Cancer hospitals Clinical trials Support Diet

Know your cancer

Understand your report Medical words explained Cancer treatments explained First week checklist Questions to ask

How to pay

Paying for treatment Help with medicine costs Insurance and appeals

Advanced therapies

Second opinions Top cancer centers Newer treatments Not approved for you yet

OpenCare

Get your plan My record How OpenCare works For doctors

Vivonco

Talk to us Newsletter Your health data privacy policy Sources and credits

Not medical advice; your doctor decides. Sources and credits. © 2026 Vivonco.